Abstract: OBJECTIVE To systematically evaluate the effect of the Shenqi Fuzheng Injection(SFI) combined with chemotherapy on immune function in treatment of advanced non-small cell lung cancer(NSCLC). METHODS Through searching the Pubmed, the Cochrane Library, CNKI, VIP, Wangfang Data, CBM, recruited randomized controlled trials(RCTs) related to the immune impact of SFI combined with chemotherapy for advanced NSCLC. The quality of included studies was assessed by 2 independent researchers according to the criteria recommended by the Cochrane Collaboration’s Interventions and Meta analyses was conducted using RevMan5.3 software. RESULTS A total of 18 randomized controlled trials involving 1 370 patients were included in the study. The result of Meta analysis showed: the immune parameters of SFI plus chemotherapy group such as CD3⁺, CD4⁺, CD4⁺/CD8⁺, NK cells were significantly higher than chemotherapy group. Its SMD and 95%CI were 3.25, (2.23, 4.27), P<0.01, 3.02, (2.16, 3.87), P<0.01, 1.3, (0.89, 1.70), P<0.01, 1.74, (1.15, 2.33), P<0.01. The difference between 2 groups had no statistical significance in immune parameters CD8⁺SMD=0.32, 95%CI=(-0.53,1.17), P=0.46. CONCLUSION SFI combined with chemotherapy has significant clinical value in improving the immune function of NSCLC patients. However, more high-quality and big-sample RCTs are required to be evaluated systematically.